Press Release

Glythera licenses novel payload class from Cancer Research UK for the development of next-generation antibody drug conjugates

Glythera gains exclusive access to Cancer Research UK’s novel CDK11 inhibitor programme for the development of ADCs conjugated using its highly stable conjugation platform, PermaLink® Glythera will generate multiple ADCs with improved therapeutic index directed towards antigens specific to difficult-to-treat tumours, combining CDK11 inhibitors with its growing in-house antibody portfolio Glythera Limited (Glythera), the next generation antibody drug conjugate (ADC) development company, and Cancer Research UK* today announced an agreement giving Glythera exclusive, worldwide rights to the charity’s novel CDK11…

Read more>>

Glythera and IONTAS enter into license agreement for the development of multiple antibodies for next-generation Antibody Drug Conjugates

IONTAS will provide Glythera with antibodies from its fully human antibody libraries Glythera will use these antibodies, in combination with its novel toxin portfolio, to develop next generation ADCs with improved efficacy and safety, to target difficult-to-treat tumours Cambridge and Newcastle, UK, 20th September, 2017: Glythera Limited (‘Glythera’), the next generation Antibody Drug Conjugate (‘ADC’) development Company, and IONTAS Limited (IONTAS), a leader in services and platform technologies associated with the discovery and optimisation of fully human antibody drugs, today…

Read more>>

Glythera appoints Dr Mike Owen as non-executive director

Glythera Limited (‘Glythera’), the next generation antibody drug conjugate (‘ADC’) development company, is pleased to announce the appointment of Dr Mike Owen to the Board as a non-executive director with immediate effect. Mike brings over 15 years of experience in the development and commercialisation of biopharmaceuticals. He was previously Senior Vice President and global Head of Research of the Biopharmaceuticals R&D Unit  at GlaxoSmithKline and was responsible for initiating and rapidly growing GSK's robust pre-clinical and clinical therapeutic antibody pipeline…

Read more>>